You are here: Home: Audio Program Guide: BCU 7 | 2007 Audio: BCU 7 | 2007
 
  Go to interview with Ian E Smith, MD
Go to interview with Charles L Vogel, MD
Go to interview with Sandra M Swain, MD
Go to interview with Paul E Goss, MD, PhD
Go to interview with Hannah M Linden, MD
 


To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Ian E Smith, MD
Professor of Cancer Medicine
Department of Medicine, Breast Unit
The Royal Marsden Hospital
London and Surrey
United Kingdom		  
  Click here to download the entire interview  
Track 1 Clinical benefits of neoadjuvant endocrine therapy
Track 2 Molecular predictors of long-term outcome after neoadjuvant therapy
Track 3 POETIC Trial: PeriOperative Endocrine Therapy for Individualizing Care
Track 4 Tissue gene expression alterations with short-term endocrine therapy
Track 5 Rationale for combined inhibition of aromatase and growth factors
Track 6 Mechanism of antitumor activity of fulvestrant

Track 7 Utilizing vaginal estrogens in patients receiving aromatase inhibitors (AIs)
Track 8 Biologic implications of AI therapy in young women with amenorrhea
Track 9 AIs and LHRH agonists as adjuvant therapy for premenopausal patients
Track 10 A UK perspective on the role of capecitabine in metastatic breast cancer
Track 11 Treatment algorithm for hormone-resistant, ER-positive disease
Track 12 Use of adjuvant trastuzumab in 2007
Track 13 Clinical efficacy and tolerability of adjuvant TCH
Track 14 Natural history of node-negative, HER2-positive subcentimeter tumors
Track 15 Investigating sequential endocrine treatment algorithms in the adjuvant setting
Track 16 Tamoxifen, AIs and cardiac events
Track 17 Endocrinology of male breast cancer
     
Charles L Vogel, MD
Senior Research Advisor for Breast Cancer
Aptium Oncology
Lynn Regional Cancer Center West Campus
Boca Raton Community Hospital
Scientific Advisor, Cancer Research Network Inc
Boca Raton, Florida
  
  Click here to download the entire interview  
Track 1 Second opinion case: A 74-year-old man initially treated with mastectomy and adjuvant chemotherapy followed by tamoxifen for a node-positive infiltrating ductal carcinoma (IDC) presents with metastatic disease
Track 2 SWOG-S0511 Phase II study of goserelin with anastrozole in advanced male breast cancer
Track 3 Fulvestrant in male breast cancer
Track 4 Second opinion case: A 53-year-old woman with a newly diagnosed 2.2-cm, ER-negative, PR-positive IDC associated with lymphovascular invasion and one of 16 positive nodes
Track 5 US Oncology Phase III trial of adjuvant TC versus TAC
Track 6 Weekly compared to every three-week taxane dosing
Track 7 Complications of corticosteroid premedications

Track 8 Randomized Phase II study comparing nab paclitaxel to docetaxel
Track 9 Selecting endocrine therapy in the presence of chemotherapy-induced amenorrhea
Track 10 Chemotherapy with bevacizumab for first-line metastatic disease
Track 11 Overview of XCaliBr: Phase II trial of capecitabine and bevacizumab
Track 12 Practical use and future directions with capecitabine in advanced breast cancer
Track 13 Second opinion case: A 64-year-old woman with an ER-positive, PR-positive, HER2-negative, node-positive IDC treated with FAC 100 followed by anastrozole
Track 14 Presentation and management of AI-associated arthralgias
audio
Track 15 Second opinion case: A 45-year-old premenopausal woman with ER-negative, PR-negative, HER2-negative inflammatory breast cancer and a 5-cm palpable lymph node
audio
Track 16 The evolving role of platinum salts in breast cancer
audio
Track 17 Clinical trial data in triple-negative disease
audio
Track 18 Second opinion case: A 53-year-old woman with mild hypertension and a 0.8-cm, poorly differentiated ER-negative, PR-negative, HER2-positive, lymph node-negative breast tumor
audio
Track 19 Treatment options for ER-positive, HER2-positive disease
audio
Track 20 Sorting out the TOPO II puzzle
audio
Track 21 Next-generation adjuvant trials with trastuzumab
audio
Track 22 Subclinical brain metastases in primary HER2-positive breast cancer
audio
     
Sandra M Swain, MD
Professor of Medicine, Georgetown University
Medical Director, Washington Cancer Institute
Washington Hospital Center
Washington, DC 		 
  Click here to download the entire interview  
Track 1 Second opinion case: A 58-year-old postmenopausal woman with triple-negative medullary carcinoma and liver metastases
Track 2 Rationale for EGFR-targeted agents in triple-negative breast cancer
Track 3 Clinical insights from patients with unique and durable responses to therapy
Track 4 Second opinion case: A 65-year-old woman with a 5-cm, lobular, ER-positive, PR-positive, HER2-negative, sentinel lymph node-negative IDC who wished to avoid chemotherapy
Track 5 Utility of Oncotype DX™ for larger tumors
Track 6 TC in node-negative early breast cancer

Track 7 Long-term cardiac sequelae with adjuvant anthracyclines
Track 8 Second opinion case: An 86-year-old woman with mild Parkinson’s disease and hypertension found to have a 1.9-cm, ER-negative, PR-negative, HER2-positive, lymph node-positive IDC
Track 9 Basis for trastuzumab monotherapy
Track 10 Quantitative measurement of ER in the setting of HER2 positivity

     
     
Paul E Goss, MD, PhD
Professor of Medicine, Harvard Medical School
Director, Breast Cancer Program, MGH Cancer Center
Co-director of the Breast Cancer Disease Program, DF/HCC
Avon Foundation Senior Scholar
Boston, Massachusetts
  
  Click here to download the entire interview  
Track 1 Pathophysiology of estrogen as a fundamental driver of breast cancer development
Track 2 Enzyme polymorphisms and cancer susceptibility patterns
Track 3 Correlative studies within NCIC-MA27 Phase III trial of adjuvant exemestane versus anastrozole
Track 4 Tumor cell adaptation to alterations in circulating estrogen levels
Track 5 Novel strategies to overcome cellular estrogen resistance
Track 6 Upregulation of HER2 at disease progression on endocrine therapy

Track 7 Clinical trials evaluating fulvestrant and anastrozole as complete estrogen blockade
Track 8 CAT trial: Combination Atamestane and Toremifene versus letrozole
Track 9 Clinical utility of tamoxifen at the time of AI failure
Track 10 Anecdotal response to AI withdrawal: Rationale for further study

Track 11 Role of extended adjuvant therapy in hormone-dependent breast cancer
Track 12 Understanding the chronicity of breast cancer recurrence
Track 13 TEACH trial: Extended adjuvant lapatinib or placebo in trastuzumab-naïve, HER2-positive early breast cancer
Track 14 Clinical significance of the progesterone receptor
Track 15 Molecular signatures predictive of endocrine response
Track 16 Impact of tumor grade on Oncotype DX recurrence score

Track 17 HOXB13:IL17BR two-gene molecular signature as a prognostic factor in breast cancer
Track 18 Genetic markers of platinum sensitivity in triple-negative breast cancer
Track 19 Neoadjuvant bevacizumab with cisplatin in triple-negative disease
     
     
Hannah M Linden, MD
Associate Professor of Medicine
University of Washington
Harborview Medical Center
Seattle Cancer Care Alliance
Seattle, Washington

  
  Click here to download the entire interview  
Track 1 Functional estrogen receptor imaging through PET technology
Track 2 Monitoring the in vivo effects of endocrine therapy through FES-PET imaging
Track 3 Identifying drivers of proliferation among ER-positive, HER2-positive breast tumors
Track 4 Integrating imaging technology into neoadjuvant trials
Track 5 Mechanisms of resistance to AI therapy
Track 6 Combined ovarian suppression and aromatase inhibition in premenopausal early breast cancer

Track 7 Ensuring effective ovarian suppression with LHRH agonists
Track 8 Current management and future advances in adjuvant endocrine therapy
Track 9 Vitamin D deficiency and bone or joint pain
Track 10 Strategies to maintain therapy in the setting of AI-associated arthralgia

Track 11 Exploiting the full potential of endocrine therapy in metastatic disease
Track 12 Patient considerations in the selection of first-line chemotherapy for metastatic disease
Track 13 Incorporating bevacizumab into the treatment algorithm
Track 14 Clinical trial data with nab paclitaxel
Track 15 The impact of corticosteroid premedication on patient quality of life
Track 16 The evolving role of TC and other nonanthracycline adjuvant regimens

Track 17 Tailoring cancer care to environmental, social and racial diversity
Track 18 Clinical research participation among vulnerable patient populations
Track 19 The contributory roles of health literacy, economics and denial on the presentation of neglected tumors
Track 20 A breast cancer telephone help line for practicing community oncologists